Resonant (RESN) 10-Q 13 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 07, 2018
Document and Entity Information
Entity Registrant Name	Resonant Inc
Entity Central Index Key	1,579,910
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		27,090,893

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 17,470,000	$ 19,524,000
Accounts receivable	52,000	50,000
Prepaid expenses and other current assets	397,000	536,000
Restricted cash	0	100,000
Investments held-to-maturity	8,884,000	0
TOTAL CURRENT ASSETS	26,803,000	20,210,000
PROPERTY AND EQUIPMENT
Property and equipment	3,473,000	3,212,000
Less: Accumulated depreciation and amortization	(1,693,000)	(1,858,000)
PROPERTY AND EQUIPMENT, NET	1,780,000	1,354,000
NONCURRENT ASSETS
Intangible assets, net	1,343,000	1,353,000
Restricted cash	211,000	0
Goodwill	819,000	824,000
Deferred income taxes	21,000	0
Other assets	69,000	19,000
TOTAL NONCURRENT ASSETS	2,463,000	2,196,000
TOTAL ASSETS	31,046,000	23,760,000
CURRENT LIABILITIES
Accounts payable	698,000	708,000
Accrued expenses	419,000	314,000
Accrued salaries and payroll related expenses	1,361,000	1,936,000
Deferred revenue	187,000	143,000
TOTAL CURRENT LIABILITIES	2,665,000	3,101,000
LONG-TERM LIABILITIES
Deferred rent	57,000	10,000
Deferred income taxes	0	1,000
TOTAL LIABILITIES	2,722,000	3,112,000
Commitments and contingencies (Note 9)	0	0
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 47,000,000 authorized and 19,511,276 outstanding as of December 31, 2017, and 27,040,714 outstanding as of September 30, 2018	27,000	20,000
Preferred stock, $0.001 par value, 3,000,000 authorized and none outstanding as of December 31, 2017 and September 30, 2018	0	0
Additional paid-in capital	114,000,000	88,447,000
Accumulated other comprehensive loss	(12,000)	(7,000)
Accumulated deficit	(85,691,000)	(67,812,000)
TOTAL STOCKHOLDERS’ EQUITY	28,324,000	20,648,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 31,046,000	$ 23,760,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	47,000,000	47,000,000
Common stock, shares outstanding	27,040,714	19,511,276
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
REVENUES	$ 115,000	$ 106,000	$ 396,000	$ 482,000
OPERATING EXPENSES
Research and development	3,584,000	2,336,000	10,185,000	6,956,000
General and administrative	3,002,000	1,978,000	8,500,000	6,939,000
TOTAL OPERATING EXPENSES	6,586,000	4,314,000	18,685,000	13,895,000
NET OPERATING LOSS	(6,471,000)	(4,208,000)	(18,289,000)	(13,413,000)
OTHER INCOME, NET
Interest and investment income	177,000	14,000	323,000	39,000
Other income (expense)	8,000	(6,000)	4,000	(7,000)
TOTAL OTHER INCOME, NET	185,000	8,000	327,000	32,000
LOSS BEFORE INCOME TAXES	(6,286,000)	(4,200,000)	(17,962,000)	(13,381,000)
Benefit from income taxes	(11,000)	(16,000)	(19,000)	(40,000)
NET LOSS	(6,275,000)	(4,184,000)	(17,943,000)	(13,341,000)
Foreign currency translation adjustment, net of tax	10,000	(17,000)	(5,000)	46,000
COMPREHENSIVE LOSS	$ (6,265,000)	$ (4,201,000)	$ (17,948,000)	$ (13,295,000)
NET LOSS PER SHARE - BASIC AND DILUTED (in dollars per share)	$ (0.23)	$ (0.28)	$ (0.73)	$ (0.94)
Weighted average shares outstanding-basic and diluted (in shares)	27,006,046	14,757,688	24,645,658	14,233,774

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity
Cumulative effect due to adoption of new accounting standard, net of tax	$ 64			$ 64
Balance (in shares) at Dec. 31, 2017	19,511,276	19,511,276
Beginning Balance at Dec. 31, 2017	$ 20,648	$ 20	$ 88,447	(67,812)	$ (7)
Increase (Decrease) in Stockholders' Equity
Vesting of restricted stock units (in shares)		621,263
Stock-based compensation	4,096		4,096
Sales of common stock, net of offering costs (in shares)		6,571,428
Sales of common stock, net of offering costs	21,190	$ 7	21,183
Exercise of warrants (in warrants)		89,142
Exercise of warrants	$ 260		260
Common stock issued in exchange for warrants (in shares)	242,913
Exercise of stock options (in shares)		4,692
Exercise of stock options	$ 14		14
Net loss	(17,943)			(17,943)
Foreign currency translation adjustment, net of tax	$ 5				5
Balance (in shares) at Sep. 30, 2018	27,040,714	27,040,714
Ending Balance at Sep. 30, 2018	$ 28,324	$ 27	$ 114,000	$ (85,691)	$ (12)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (6,275,000)	$ (4,184,000)	$ (17,943,000)	$ (13,341,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			600,000	554,000
Deferred tax benefit			(41,000)	(40,000)
Stock-based compensation			3,958,000	2,024,000
Non-cash loss on disposal of assets			8,000	0
Non-cash investment income			(63,000)	0
Non-cash patent write-off			87,000	0
Changes in assets and liabilities:
Accounts receivable			(2,000)	(9,000)
Prepaid expenses and other current assets			206,000	(112,000)
Other assets			(50,000)	(3,000)
Accounts payable			88,000	113,000
Accrued expenses			(82,000)	86,000
Accrued salaries and payroll related expenses			(437,000)	159,000
Deferred revenue			46,000	(67,000)
Deferred rent			47,000	(12,000)
Net cash used in operating activities			(13,578,000)	(10,648,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of fixed assets			16,000	0
Purchases of property and equipment			(865,000)	(494,000)
Expenditures for patents and domain names			(157,000)	(244,000)
Redemption of investments held-to-maturity			39,590,000	4,747,000
Purchase of investments held-to-maturity			(48,411,000)	0
Net cash provided by (used in) investing activities			(9,827,000)	4,009,000
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from the sale of common stock from private placement offering			0	15,025,000
Net proceeds from the sale of common stock from underwritten public offering			21,190,000	0
Proceeds from exercise of stock options			14,000	54,000
Proceeds from exercise of warrants			260,000	0
Net cash provided by financing activities			21,464,000	15,079,000
Effects of exchange rates on cash, cash equivalents and restricted cash			(2,000)	6,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			(1,943,000)	8,446,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period			19,624,000	5,184,000	$ 5,184,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period	17,681,000	13,630,000	17,681,000	13,630,000	19,624,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Taxes Paid			3,000	1,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Issuance of common stock in settlement of liability			1,004,000	272,000
Stock options issued in settlement of liability			0	580,000
Property and equipment included in accounts payable			124,000	30,000
Property and equipment included in accrued liabilities			282,000		0
Patents included in accounts payable			32,000	33,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash and cash equivalents						$ 17,470,000	$ 19,524,000	$ 13,530,000
Restricted cash						0	100,000	100,000
Restricted cash						211,000	0
Total cash, cash equivalents and restricted cash	$ 17,681,000	$ 13,630,000	$ 19,624,000	$ 5,184,000	$ 5,184,000	$ 17,681,000	$ 19,624,000	$ 13,630,000

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Resonant Inc. is a late-stage development company located in Goleta, California. We were incorporated in Delaware in January 2012 as a wholly owned subsidiary of Superconductor Technologies Inc., or STI. Resonant LLC, a limited liability company, was formed in California in May 2012. We changed our form of ownership from a limited liability company to a corporation in an exchange transaction in June 2013, when we commenced business. We are the successor of Resonant LLC. We completed our initial public offering, or IPO, on May 29, 2014. On July 6, 2016 we acquired all of the issued and outstanding capital stock of GVR Trade S.A, or GVR. GVR is a wholly owned subsidiary of Resonant Inc. We have created an innovative software, intellectual property, or IP, and services platform that has the ability to increase designer efficiency, reduce the time to market and lower unit costs in the designs of filters for radio frequency, or RF, front-ends for the mobile device industry. The RF front-end, or RFFE, is the circuitry in a mobile device responsible for analog signal processing and is located between the device’s antenna and its digital circuitry. The software platform we are developing is based on fundamentally new technology that we call Infinite Synthesized Networks ® , or ISN ® , to configure and connect resonators, the building blocks of RF filters. Filters are a critical component of the RF front-end used to select desired radio frequency signals and reject unwanted signals. Our ISN ® platform allows us to develop unique, custom designs that address the increasing complexity of the RFFE due to carrier aggregation (the combining of multiple frequencies into a single data stream to increase throughput through higher data rates), or CA, by both reducing the size of the filter and improving performance. Our goal is to utilize our ISN ® platform to support our customers in reducing their time to develop complex filter and module designs, to access new classes of filter designs, and to do it more cost effectively. Additionally, our ISN ® platform has allowed us to expand our customer focus beyond just filter manufacturers by enabling a new class of customer - fabless filter manufacturers. These companies do not have their own internal filter fabrication facility, or Fab, and typically already would be supplying other products in the RFFE to the OEMs and as a result do not require a protracted, new vendor, qualification process in order to supply parts. It is through our existing customer relationships that we are able to facilitate these third-party Fab relationships, that leverage our ISN ® tools to deliver cutting edge filter designs to these fabless filter customers. In the second quarter of 2018 Resonant deployed the first ever module of the company’s ISN tool for evaluation, PMTx TM , designed to significantly improve design and fabrication turn times. We are commercializing our technology through the creation of filter designs that address the problems in the high growth RFFE industry created by the growing number of frequency bands in mobile devices. The worldwide adoption of Long Term Evolution, or LTE, as the global standard, and the use of mobile devices to access the Internet, has resulted in massive proliferation of frequency bands which, when combined with CA for higher data rates and multiple input multiple output, or MIMO, has resulted in an ever-increasing number and complexity of filters in the RFFE. We have developed and continue to expand a series of single-band designs for frequency bands presently dominated by larger and more expensive bulk acoustic wave, or BAW, filters. We are also developing multiplexer filter designs for two or more bands to address the CA requirements of our customers. We are using our ISN ® platform to efficiently integrate these designs into RF modules for our module customers. Finally, we are developing unique filter designs, enabled by ISN ® , to replace multiple filters and associated componentry for many bands, with higher performance. Currently, we are leveraging ISN ® to develop these designs targeted for either the Surface Acoustic Wave (SAW) or Temperature Compensated, Surface Acoustic Wave (TC-SAW) manufacturing processes. In 2018 we further extended ISN for BAW designs. This has resulted in the invention of a unique resonator structure, XBAR TM , which exhibits performance parameters suitable for 5G applications - high frequency operation, large bandwidth and high power reliability. In order to succeed, we must convince RFFE suppliers that our filter designs can significantly reduce the size and cost of their products. We believe licensing our designs is the most direct and effective means of validating our ISN ® platform and related IP libraries to address this rapidly growing market. Our target customers make part or all of the RFFE. We intend to retain ownership of our designs, and we expect to be compensated through license fees and royalties based on sales of RFFE filters that incorporate our designs. In addition, we charge our licensees a nominal upfront fee for allocation of design resources to their project. Capital Resources and Liquidity We are using the net proceeds from the sales of our common stock for product development to commercialize our technology, research and development, the development of our patent strategy and expansion of our patent portfolio, as well as for working capital and other general corporate purposes. Our costs include employee salaries and benefits, compensation paid to consultants, capital costs for research and other equipment, costs associated with development activities including travel and administration, legal expenses, sales and marketing costs, general and administrative expenses, and other costs associated with a late-stage development, publicly-traded technology company. However, this is highly dependent on the nature of our development efforts and our success in commercialization. We continue to add employees to support the development of our ISN ® platform, applications and system test, research and development, as well as general and administrative functions, to support our efforts. Additionally, we continue to incur consulting expenses related to technology development and other efforts as well as legal and related expenses to protect our intellectual property. The amounts that we actually spend for any specific purpose may vary significantly and will depend on a number of factors including, but not limited to, our expected cash resources, the pace of progress of our commercialization and development efforts, actual needs with respect to product testing, research and development, market conditions, and changes in or revisions to our marketing strategies. In addition, we may invest in complementary products, technologies or businesses. We have earned minimal revenues since inception, and our operations have been funded with initial capital contributions and proceeds from the sale of equity securities and debt. At December 31, 2017 and September 30, 2018 , we had incurred accumulated losses of $67.8 million and $85.7 million , respectively. The losses are primarily the result of research and development costs associated with commercializing our technology, combined with start-up, financing and public company costs. We expect to continue to incur substantial costs for commercialization of our technology on a continuous basis because our business model involves developing and licensing custom filter designs. Our condensed consolidated financial statements account for the continuation of our business as a going concern. We are subject to the risks and uncertainties associated with a new business. Our principal sources of liquidity as of September 30, 2018 consist of existing cash and cash equivalents of $17.5 million and $8.9 million in investments. In the nine months ended September 30, 2018 , we used approximately $14.6 million in cash and investments. Due to these conditions, substantial doubt exists as to our ability to continue as a going concern. After evaluation of these conditions, we believe our current resources, in the absence of material revenues, will provide sufficient funding for planned operations into the second half of 2019 . If necessary, we will seek to raise additional capital from the sale of equity securities or the incurrence of indebtedness to allow us to continue operations. There can be no assurance that additional financing will be available to us on acceptable terms, or at all. Additionally, if we issue additional equity securities to raise funds, whether to existing investors or others, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. Additionally, we may be limited as to the amount of funds we can raise pursuant to Securities and Exchange Commission, or SEC, rules and the continued listing requirements of NASDAQ. If we cannot raise needed funds, we might be forced to make substantial reductions in our operating expenses, which could adversely affect our ability to implement our business plan and ultimately our viability as a company. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates —The accompanying condensed consolidated financial statements at September 30, 2018 and for the three and nine months ended September 30, 2017 and 2018 are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Prior period figures have been reclassified, wherever necessary, to conform to current presentation. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2017 have been derived from our audited consolidated financial statements as of that date. The condensed consolidated financial statements included herein have been prepared by us pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017 . Our operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included. Consolidation —The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR Trade, S.A. All significant intercompany balances and transactions have been eliminated. Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents. Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR Trade S.A., our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held. Restricted Cash —Restricted cash at December 31, 2017 consisted of a $100,000 certificate of deposit with a financial institution, which served as collateral for our corporate credit cards. During the nine months ended September 30, 2018 we terminated the corporate credit card program for which the certificate of deposit was held and thus the restriction was lifted. As of September 30, 2018 our restricted cash balance consists of a $211,000 pledged mutual fund account which is held as collateral against a letter of credit issued in May 2018 in connection with the lease of our corporate headquarters. Effective January 1, 2018, we adopted ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash , which requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Consequently, restricted cash is included in the beginning and ending cash balances on the statement of cash flows. See also Note 9- Commitments and Contingencies, for further details. Investments —Securities held-to-maturity: Management determines the appropriate classification of securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in interest and investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in net securities gains (losses). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in net securities gains (losses). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income. During 2017 , we invested in commercial papers and certificates of deposit that were classified as held-to-maturity. Additionally, we maintained money market fund balances that were classified as cash and cash equivalents. As of September 30, 2017 , all of the investments had matured and there were no investments classified as held-to-maturity. We recorded investment income of $14,000 and $39,000 for the three and nine months ended September 30, 2017, respectively, associated with the investments. During 2018 , we invested in U.S. Treasury bills, commercial papers and a certificate of deposit that were classified as investments held-to-maturity. Additionally, we maintained money market fund balances that were classified as cash and cash equivalents. As of September 30, 2018 , the amortized cost value and fair value are $8.9 million with zero unrealized gain or loss. U.S. Treasury bills totaling $25.0 million matured in April 2018 and certain commercial papers totaling $14.7 million matured during the nine months ended September 30, 2018. Remaining commercial papers totaling $8.8 million mature in January 2019, and the certificate of deposit for $100,000 matures in January 2019 . We have not recognized an other-than-temporary impairment gain or loss or a comprehensive gain or loss-to-date. We recorded interest and investment income of $177,000 and $323,000 for the three and nine months ended September 30, 2018 , respectively, associated with our cash and investment accounts. Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exit price notion, or price that would be received for an asset or paid to transfer a liability, in an orderly transaction between the market participants at the measurement date. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact ability to collect the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. There was no allowance for doubtful accounts at December 31, 2017 and September 30, 2018 . Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to six years. Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2017 and September 30, 2018 , intangible assets, net, includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or are abandoned as we no longer plan to pursue them. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses. During the three and nine months ended September 30, 2018, we wrote off $39,000 and $87,000 , respectively, related to expired and abandoned patents. Goodwill— At December 31, 2017 and September 30, 2018 , goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Revenue Recognition —As of January 1, 2018, we recognize revenue in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers. Revenue is recognized upon the transfer of control of promised goods or services to the customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of fees received in connection with filter design projects with customers. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue over the course of the design development phase as our customers are able to benefit from our design services as they are provided, primarily by marketing the in-process design to their customers. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. In most cases, our design services are performed over a period of six to twelve months. Contracts generally include upfront non-refundable fees, intended to support our initial engineering product development efforts, as well as milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. At contract inception, we assess the likelihood of achieving milestones to estimate the total consideration we believe we will receive for our services. Our design service contracts also include a functional license over the completed design, which enables our customer to use our design in products marketed to their customers. We also earn royalties for each product shipped by our customer that incorporates one of our designs. Royalty fees are recorded upon shipment by our customer, and payment is generally due within 30 days. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. During the three months ended September 30, 2017 and September 30, 2018 , we recorded revenue of $106,000 and $115,000 , respectively. During the nine months ended September 30, 2017 and September 30, 2018 , we recorded revenue of $482,000 and $396,000 , respectively. As of September 30, 2018 , we have recorded $187,000 in deferred revenue. See Note 3- Revenue Recognition, for further details. Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development . Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We recognize rent expense under such leases on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the lease term. Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered. In the case of award modifications, we account for the modification in accordance with ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , whereby we recognize the effect of the modification in the period the award is modified. Stock-based compensation expense is included in research and development expenses and general and administrative expenses. Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards. The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Nine Months Ended September 30, 2017 2018 Common stock warrants 6,202,147 3,385,100 Common stock options 908,560 1,234,967 Non-vested restricted stock unit awards 1,401,693 2,071,299 Total shares excluded from net loss per share attributable to common stockholders 8,512,400 6,691,366 Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2017 and September 30, 2018 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the three and nine months ended September 30, 2017 and 2018. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome would be unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows. Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive loss in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive loss in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss. Recent Accounting Pronouncements Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases , which provides clarity to certain narrow aspects of the new standard and ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides an optional transition method for adopting the new leases guidance that eliminates comparative period reporting under the new guidance in the year of adoption. . The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We plan to adopt the standard, as well as the practical expedients included therein, as of January 1, 2019. We have reviewed our leases and other agreements in order to determine the effects of the new guidance on our consolidated financial statements. We have determined that we have two facility leases that meet the criteria for recognition of lease assets and lease liabilities on the balance sheet under the new guidance. We are not party to any leases for which we are the lessor. We believe the adoption will cause us to recognize a significant right-of-use asset as well as the related lease liability in our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements. Compensation-Stock Compensation— In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting , which intends to align the accounting of share-based payment awards issued to employees and non-employees. This update will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. Early adoption is permitted. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements as we have very few share-based payment arrangements with non-employees.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Disaggregation of Revenue [Abstract]
Revenue recognition	REVENUE RECOGNITION On January 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers, and all of the related amendments and applied it to all contracts using the modified retrospective method. We recognized the cumulative effect of the initial adoption as an adjustment to the opening balance of retained earnings. Comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. The adoption of the guidance resulted in a change in the accounting for milestone payments. Previously, we recognized revenue upon the achievement of a milestone. Under ASC Topic 606, milestone payments are treated as variable consideration and included in the transaction price for our design services. The cumulative effect of the changes made to our condensed consolidated balance sheet as of January 1, 2018 for the adoption of the new standard was as follows: BALANCE SHEET Balance at December 31, 2017 Adjustments Due to ASC 606 Balance at January 1, 2018 ASSETS Prepaid expenses and other current assets $ 536,000 $ 67,000 $ 603,000 LIABILITIES AND STOCKHOLDERS' EQUITY Deferred Revenue, current $ 143,000 $ 3,000 $ 146,000 Retained Earnings $ (67,812,000 ) $ 64,000 $ (67,748,000 ) The following table summarizes the impact of the adoption on our Condensed Consolidated Balance Sheet and Condensed Consolidated Statement of Comprehensive Loss as of and for the periods ended September 30, 2018: September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Increase/(Decrease) BALANCE SHEET ASSETS Prepaid expenses and other current assets $ 397,000 $ 394,000 $ 3,000 LIABILITIES AND STOCKHOLDERS' EQUITY Deferred revenue, current $ 187,000 $ 160,000 $ 27,000 Accumulated deficit $ (85,691,000 ) $ (85,667,000 ) $ (24,000 ) Three Months Ended September 30, 2018 As Reported Activity Without Adoption of ASC 606 Effect of Change Increase/(Decrease) STATEMENT OF COMPREHENSIVE LOSS Revenue $ 115,000 $ 155,000 $ (40,000 ) Net loss $ (6,275,000 ) $ (6,235,000 ) $ 40,000 Nine Months Ended September 30, 2018 As Reported Activity Without Adoption of ASC 606 Effect of Change Increase/(Decrease) STATEMENT OF COMPREHENSIVE LOSS Revenue $ 396,000 $ 484,000 $ (88,000 ) Net loss $ (17,943,000 ) $ (17,855,000 ) $ 88,000 Our contracts with customers primarily relate to the design of filters for radio frequency, or RF, front-ends for the mobile device industry. Design service contracts generally include a modest upfront payment for the design services and a license over the completed design. We retain ownership of our designs, and therefore are also compensated for our design services through royalties based on sales of RFFE filters that incorporate our designs. We currently do not manufacture or sell any physical products or operate as a contract design company developing designs for a fee. Except for the royalty fees that are recognized as revenue upon use of one of our designs, we recognize revenue related to our design services over the estimated design completion time, on a straight-line basis, as the services are performed. The design development period varies significantly, from 9 to 36 months, depending upon the difficulty of the design. Other Judgments and Assumptions - We apply the practical expedients available in ASC 606 to not disclose information about 1) remaining performance obligations that have original expected durations of one year or less and 2) variable consideration that is a sales-based or usage-based royalty. Royalty Revenue - Upon completion of design services, our customers retain a license over the completed design. The license will typically last for a minimum of two years, and in many cases for the life of the design. Royalties are sales-based, and we recognize royalty revenue upon shipment, by our customer, of products that include our licensed design. In some cases, we will receive a reduced royalty amount due to value add, or other taxes, associated with the royalty. Taxes related to royalties are netted against revenues. Contract Assets - Contract assets, other than accounts receivable, consist of unbilled revenue and generally arise when revenue is recognized on a contract whose transaction price includes an estimate of variable consideration from milestone payments. We do not have material amounts of contract assets as we have relatively few contracts, only modest design service fees and a small number of contracts containing milestone payments. Contract asset balances are included in Prepaid expenses and other current assets in our Condensed Consolidated Balance Sheet. Contract Liabilities - Our contract liabilities consist of customer deposits and deferred revenue. We classify contract liabilities as current or noncurrent based on the timing of when we expect to recognize revenue. Generally, our contract liabilities are expected to be recognized in one year or less. Customer deposits and deferred revenue are separately stated in our Condensed Consolidated Balance Sheet. Summary of changes in contract assets and liabilities for the period from January 1, 2018 to September 30, 2018: Contract asset Contract asset, January 1, 2018 $ 67,000 Contract assets at beginning of year transferred to accounts receivable (43,000 ) Reversal of contract assets due to changes in transaction price (24,000 ) Contract assets recorded on contracts during the period 3,000 Contract asset, September 30, 2018 $ 3,000 Contract liability Contract liability, January 1, 2018 $ 146,000 Recognition of revenue included in beginning of year contract liability (92,000 ) Contract liability, net of revenue recognized on contracts during the period 132,000 Foreign currency translation 1,000 Contract liability, September 30, 2018 $ 187,000 The following table presents our disaggregated revenue by region and source: Three Months Ended September 30, Nine Months Ended September 30, 2017 2018 2017 2018 Revenue by geographic region: United States $ 89,000 $ 96,000 $ 415,000 $ 338,000 Switzerland 17,000 19,000 67,000 58,000 Total revenue $ 106,000 $ 115,000 $ 482,000 $ 396,000 Revenue by source: Design services $ 99,000 $ 85,000 $ 465,000 $ 276,000 Royalties 7,000 30,000 17,000 120,000 Total revenue $ 106,000 $ 115,000 $ 482,000 $ 396,000

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	WARRANTS From time to time, we have issued warrants to purchase shares of common stock. These warrants have been issued in connection with the financing transactions and consulting services. Our warrants are subject to standard anti-dilution provisions applicable to shares of our common stock. Bridge Warrants In January and March 2013, as an inducement to make bridge loans to the company, our founders received warrants to purchase a total of 124,998 units of Resonant LLC (the form of the Company at that time) at an exercise price of $0.40 per unit for a period of five years. We refer to these warrants as Bridge Warrants. On June 17, 2013 , in connection with our acquisition of all of the outstanding membership interests of Resonant LLC in an exchange transaction, the founders exchanged their Bridge Warrants to purchase an aggregate of 124,998 Class B units of Resonant LLC for Bridge Warrants to purchase an aggregate of 249,999 shares of our common stock at an exercise price of $0.20 per share. All other terms of the Bridge Warrants remained the same. In January 2018, we entered into an agreement with our founders to exchange all of the warrants for an amount of shares that would equal the number of shares they would have received if exercised under a cashless exercise. The effect of exchanging the warrants for shares of our common stock was considered a modification of the award which required us to record expense for the excess of the fair value of the common stock issued over the fair value of the exchanged warrants. On the date of the exchange the fair value of the warrants was determined to be $1.6 million and the fair value of the shares of common stock issued were $1.6 million . There was a difference in fair value of $2,000 which was recorded to general and administrative expenses during the nine months ended September 30, 2018. No expense was recorded in the three months ended September 30, 2018. Private Placement Warrants - February 2017 In February 2017, we issued warrants to purchase 1,626,898 shares of our common stock at an exercise price of $8.25 in connection with our private placement sale of 1,626,898 shares of common stock. The warrants are exercisable for a period commencing 6 months and ending 30 months after the closing of the financing. We refer to these warrants as Private Placement Warrants - February 2017. We estimated the fair value of the Private Placement Warrants at $2,084,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.91 per share, time to maturity of 3 years, volatility of 60% , zero expected dividend rate and risk-free rate of 1.50% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. On December 19, 2017, we entered into a Warrant Exercise Agreement with the holder of Private Placement Warrants - February 2017 to induce the exercise of the 1,626,898 warrants in full. Pursuant to the agreement, the warrant holder exercised in full the warrant and purchased 1,626,898 shares of our common stock at an exercise price of $8.25 per share, for an aggregate exercise price of approximately $13.4 million and we paid the warrant holder an inducement fee of approximately $6.7 million , which resulted in net proceeds to us of $6.7 million . The inducement offer included in the Warrant Exercise Agreement was considered a modification to the warrant upon acceptance by the warrant holder. Upon modification of the warrant we were required to remeasure the warrant. We estimated the fair value of the Private Placement Warrants - February 2017 immediately prior to modification at $4.1 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $8.18 per share, time to maturity of 1.67 years , volatility of 60% , zero expected dividend rate and risk-free rate of 1.78% . We estimated the fair value of the Private Placement Warrants - February 2017 upon modification at $6.7 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $8.18 per share, time to maturity of 1 day , volatility of 10% , zero expected dividend rate and risk-free rate of 1.25% . The change in fair value was $4.1 million , and when combined with the cash inducement of $6.7 million , resulted in $2.6 million of expense, which was recorded as warrant inducement expense during the year ended December 31, 2017. Private Placement Warrants - September 2017 In September and October 2017, we issued warrants to purchase an aggregate of 1,976,919 shares of our common stock at an exercise price of $4.85 in connection with our private placement sale of 1,976,919 shares of common stock. The sale was completed in two tranches with the first tranche, which closed on September 28, 2017 , including 1,745,581 warrants, and the second tranche, which closed on October 2, 2017 , including 231,338 warrants. The warrants are exercisable for a period commencing 6 months and ending 36 months after the closing of the financing. Collectively, we refer to these warrants as Private Placement Warrants - September 2017. We estimated the total fair value of the Private Placement Warrants - September 2017 at $3.6 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.49 for the first tranche and $4.69 per share for the second tranche, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rates of 1.59% for the first tranche and 1.63% for the second tranche. The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. Placement Agent Warrants - 2017 In addition to the Private Placement Warrants - September 2017 issued in connection with our private placement sale of 1,976,919 shares of our common stock, we also issued to the placement agent, warrants to purchase a total of 98,846 shares of our common stock at an exercise price of $4.85 per share. Upon closing of the first tranche on September 28, 2017, we issued 87,279 warrants, and upon closing the second tranche, we issued 11,567 warrants. The warrants are exercisable for a period commencing 6 months and ending 36 months after the closing of the financing. Collectively, we refer to these warrants as Placement Agent Warrants - 2017. We estimated the fair value of the Placement Agent Warrants - 2017 at $174,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.49 per share for the first tranche and $4.69 per share for the second tranche, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rates of 1.59% for the first tranche and 1.63% for the second tranche. The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. A roll-forward of warrant share activity from January 1, 2017 to September 30, 2017 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2017 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2017 Bridge Warrants 249,999 — — 249,999 Consulting Warrants 98,000 — (41,889 ) (1) 56,111 Financing Warrants 78,186 — — 78,186 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 48,000 — (42,000 ) (2) 6,000 Private Placement Warrants - 2016 1,995,124 — (89,281 ) (3) 1,905,843 Underwriting Warrants- Public Offering 2016 135,750 — — 135,750 Private Placement Warrants - February 2017 — 1,626,898 — 1,626,898 Private Placement Warrants - September 2017 — 1,832,860 — 1,832,860 2,915,559 3,459,758 (173,170 ) 6,202,147 (1) During the nine months ended September 30, 2017, there were 41,889 common stock warrants that were exercised through cashless exercises which resulted in 41,800 shares being issued. (2) During the nine months ended September 30, 2017, 42,000 warrants expired. (3) During the nine months ended September 30, 2017, there were 89,281 common stock warrants that were exercised through cashless exercises which resulted in 37,031 shares being issued. A roll-forward of warrant share activity from January 1, 2018 to September 30, 2018 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2018 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2018 Bridge Warrants 249,999 — (249,999 ) (1) — Consulting Warrants 12,223 — (5,556 ) (2) 6,667 Financing Warrants 62,530 — — 62,530 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 6,000 — (6,000 ) (3) — Private Placement Warrants - 2016 891,063 — (73,000 ) (4) 818,063 Underwriting Warrants - Public Offering 2016 122,175 — — 122,175 Private Placement Warrants - September 2017 1,976,919 — (10,600 ) (5) 1,966,319 Placement Agent Warrants 98,846 — — 98,846 3,730,255 — (345,155 ) 3,385,100 (1) During the nine months ended September 30, 2018 , there were 249,999 warrants that were exchanged for 242,913 shares of common stock in an exchange transaction where the warrant holders exchanged the warrants for the same number of shares they would have been entitled to in a cashless exercise. (2) During the nine months ended September 30, 2018 , there were 5,556 warrants that were exercised through a cashless exercise which netted 5,542 shares of common stock being issued. (3) During the nine months ended September 30, 2018 , 6,000 warrants expired. (4) During the nine months ended September 30, 2018 , there were 73,000 warrants exercised for cash. (5) During the nine months ended September 30, 2018 , there were 10,600 warrants exercised for cash.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Common Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 47,000,000 shares of common stock. Holders of our common stock are entitled to dividends as and when declared by the Board of Directors, subject to rights and holders of all classes of stock outstanding having priority rights to dividends. There have been no dividends declared to date. Each share of common stock is entitled to one vote. On March 27, 2018 , we completed the sale of 5,714,286 shares of common stock at a price of $3.50 per share in an underwritten public offering. Gross proceeds were $20.0 million with net proceeds of $18.4 million after deducting underwriter fees and offering expenses. The shares were issued pursuant to a shelf registration statement that we filed with the SEC, which became effective in May 2016 . On April 6, 2018 , following exercise by the underwriter of its overallotment option, we sold an additional 857,142 shares at a price of $3.50 , resulting in gross proceeds of $3.0 million and net proceeds of $2.8 million after deducting underwriter fees and offering expenses. Preferred Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 3,000,000 shares of preferred stock. The Board of Directors has the authority, without action by our stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. To-date, no preferred shares have been issued.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION 2014 Omnibus Incentive Plan In January 2014, our board of directors approved the 2014 Omnibus Incentive Plan and amended and restated the plan in March 2014. Our stockholders approved the Amended and Restated 2014 Omnibus Incentive Plan, or the 2014 Plan, in March 2014. Our 2014 Plan initially permitted for the issuance of equity-based instruments covering up to a total of 1,400,000 shares of common stock. In June 2016, our board of directors and stockholders approved an increase of 1,300,000 shares and in June 2017 approved an additional increase of 3,250,000 shares of common stock bringing the total shares allowed under the plan to 5,950,000 . Option Valuation We have computed the fair value of options granted to employees and non-employees using the Black-Scholes option valuation model. The compensation costs of non-employee arrangements are subject to re-measurement at each reporting period over the vesting terms as earned. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued to employees is the estimated period of time that options granted are expected to be outstanding. We have estimated the expected life of our employee stock options using the “simplified” method, whereby, the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to our lack of sufficient historical data. For non-employees we use an estimated expected life of the remaining term of the stock option grant, which is initially ten years . Since our stock has not been publicly traded for a sufficiently long period of time, we are utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within our industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Stock Options to Employees and Non-Employees During the three and nine months ended September 30, 2017 , we granted incentive stock options for the purchase of 131,500 and 299,880 shares, respectively, of our common stock to our employees. The stock options have an exercise price range of $4.36 per share to $4.68 per share with a term of 10 years . Of the options granted in 2017, 125,880 options vested upon grant, 91,500 vested nine days after grant and the remaining 82,500 stock options vest quarterly over sixteen quarters. The options granted had an aggregate grant date fair value of $356,000 and $802,000 for the three and nine months ended September 30, 2017, respectively, utilizing the Black-Scholes option valuation model. During the three and nine months ended September 30, 2018 , we granted incentive stock options for the purchase of 110,000 and 227,500 shares, respectively, of our common stock to our employees. The stock options have an exercise price range of $4.12 per share to $5.96 per share with a term of 10 years . The stock options vest quarterly over sixteen quarters. The options granted had an aggregate grant date fair value of $345,000 and $738,000 , for the three and nine months ended September 30, 2018, respectively, utilizing the Black-Scholes option valuation model. We estimated the fair value of stock options awarded during the nine months ended September 30, 2017 and 2018 using the Black-Scholes option valuation model. The fair values of stock options granted for the periods were estimated using the following assumptions: Stock Option Grants Awarded During the Nine Months Ended September 30, 2017 Stock Option Grants Awarded During the Nine Months Ended September 30, 2018 Stock Price $4.36 to $4.68 $4.12 to $5.96 Dividend Yield 0.00% 0.00% Expected Volatility 60% 70% Risk-free interest rate 1.95% - 2.14% 2.50% - 2.98% Expected Life 7 years 7 years Stock-based compensation expense related to stock options for employees was $100,000 and $125,000 for the three months ended September 30, 2017 and 2018 , respectively, and was $332,000 and $347,000 for the nine months ended September 30, 2017 and 2018 , respectively, exclusive of options issued in connection with our incentive programs which are discussed below. For all employee stock options, we estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from our estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment in the period the estimates were revised. During the three and nine months ended September 30, 2017 and 2018 , we applied a forfeiture rate of six percent, which is reflected in our stock-based compensation expense related to stock options. In January 2017, we modified certain stock options previously granted to a former executive. The modification was made in connection with the executive’s termination. The modification included accelerated vesting of stock options to purchase 8,752 shares of common stock as well as an extension of the exercise period for all vested shares, including stock options to purchase 17,504 shares of common stock. As a result of the modification, additional stock compensation expense of $19,000 was recognized for the nine months ended September 30, 2017 . There was no expense related to the modification during the nine months ended September 30, 2018 . For stock options paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50. Non-employee stock option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these stock options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of stock options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested. Stock-based compensation expense related to stock options for consultants was $2,000 for the three months ended September 30, 2017 and was a reduction of expense of $2,000 for the three months ended September 30, 2018 . Stock-based compensation expense related to stock options for consultants was $7,000 and $6,000 for the nine months ended September 30, 2017 and 2018 , respectively, exclusive of options issued in connection with our incentive programs which are discussed below. Stock Option Award Activity The following is a summary of our stock option activity during the nine months ended September 30, 2018 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2018 1,082,490 $ 4.87 $ 3.00 8.38 Granted 227,500 4.77 3.24 9.31 Exercised (4,692 ) 2.91 1.75 — Canceled / Forfeited (70,331 ) 4.73 2.89 — Outstanding, September 30, 2018 1,234,967 $ 4.86 $ 3.06 7.95 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2018 704,303 $ 5.08 $ 3.17 8.15 Vested 114,591 4.76 2.90 7.54 Exercised (4,692 ) 2.91 1.75 — Canceled / Forfeited (17,057 ) 4.72 2.84 — Exercisable, September 30, 2018 797,145 $ 5.05 $ 3.15 7.43 The following table presents information related to stock options outstanding and exercisable at September 30, 2018 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.93 – $2.00 146,183 7.34 90,323 $3.83 – $4.92 646,984 8.63 370,907 $5.01 – $6.00 281,500 6.04 207,455 $6.18 – $7.20 70,000 6.15 53,753 $7.54 – $7.80 67,800 6.32 54,540 $8.06 – $12.98 22,500 6.30 20,167 1,234,967 7.43 797,145 As of September 30, 2018 , there was $1.2 million of unrecognized compensation expense related to unvested employee stock options, which is expected to be recognized over a weighted-average period of approximately 3.0 years . The aggregate intrinsic values of outstanding stock options and vested stock options as of September 30, 2018 were $308,000 and $190,000 , respectively, which represent options whose exercise price was less than the closing fair market value of our common stock on September 30, 2018 of $4.06 per share. Restricted Stock Units Activity We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase in fair value, if any, is recognized as expense in the period the related services are rendered. During the three months ended September 30, 2017 and 2018 we recorded $564,000 and $1.2 million , respectively, of stock-based compensation related to the restricted stock unit shares that had been issued to-date. During the nine months ended September 30, 2017 and 2018 we recorded $1.7 million and $3.3 million , respectively, of stock-based compensation related to the restricted stock unit shares that had been issued to-date. In January 2017, we modified certain restricted stock units previously granted to a former executive. The modification was made in connection with the executive’s termination. The modification included accelerated vesting of 8,815 units which resulted in additional stock compensation expense of $36,000 for the nine months ended September 30, 2017 . There was no expense related to the modification during the three and nine months ended September 30, 2018 . A summary of restricted stock unit activity for the nine months ended September 30, 2018 is as follows: Number of Restricted Share Units Weighted- Average Grant-Date Fair Value Per Share Outstanding at January 1, 2018 1,476,858 $ 4.96 Granted 1,379,905 4.81 Vested (621,263 ) 4.93 Forfeited (164,201 ) 5.16 Outstanding at September 30, 2018 2,071,299 $ 4.85 As of September 30, 2018 , there was $6.9 million of unrecognized compensation expense related to unvested restricted stock unit agreements which is expected to be recognized over a weighted-average period of approximately 2.3 years . For restricted stock unit awards subject to graded vesting, we recognize compensation cost on a straight-line basis over the service period for the entire award. Market-based Awards In August 2016, we granted 250,000 market-based restricted stock units to an executive. The restricted stock units are subject to market-based vesting requirements, measured quarterly, based on the average of (a) the average high daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter and (b) the average low daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter, each as reported by The Nasdaq Stock Market, LLC. The restricted stock units are eligible to be earned on a quarterly basis based on a linear interpolation of the applicable share price, or in the case of a liquidation event, on the day of (or in connection with) such liquidation event based on the applicable transaction price. Once earned, the restricted stock units vest 50% on the date such restricted stock units become earned and 50% on September 30, 2019 . We recognize compensation expense for restricted stock units with market conditions using a graded vesting model, based on the probability of the performance condition being met, net of estimated pre-vesting forfeitures. The share price on the date of issuance was $5.06 per share. For each of the three months ended September 30, 2017 and 2018, we recognized $6,000 of stock compensation expense in connection with this award. For the nine months ended September 30, 2017 and 2018, we recognized $19,000 and $18,000 , respectively, of stock compensation expense in connection with this award, which is included in general and administrative expenses. The unamortized expense related to this award is $24,000 and is expected to be recognized over 1.0 year. Incentive Bonus Awards We provide eligible employees, including executives, the opportunity to earn bonus awards upon achievement of predetermined performance goals and objectives. The purpose is to reward attainment of company goals and/or individual performance objectives, with award opportunities expressed as a percentage of base salary. Bonuses can be measured and paid quarterly and/or annually, and are paid in cash, equity or a combination of cash and equity, in the discretion of our compensation committee. 2017 Incentive Bonus Program During 2017, our employees and executives participated in the 2017 Incentive Bonus Program. The program provided for the award of quarterly and annual bonuses to our employees and executive officers if certain performance goals, based on company-wide billings, expenses and certain other individual non-monetary targets, were attained in quarterly and annual performance periods during our 2017 fiscal year. The awards contained a combination of service conditions and performance conditions based on the achievement of specified performance thresholds. The awards were based on each individual’s annual salary multiplied by a bonus multiplier percentage which had been determined by our compensation committee. The plan also allowed for additional discretionary awards to non-executive employees up to 10% of the total base salaries of non-executive employees. Additionally, the annual bonus, as it related to executive employees, was subject to the achievement of certain stock price thresholds for the 10 trading days ending on the last trading day of 2017. The bonuses were to be paid in the form of cash, stock options, restricted stock, or a combination thereof. The number of shares underlying equity awards granted to each employee were determined based on the performance bonus amount to be paid in equity, based in part by utilizing the stock price on the grant date. We recognized compensation expense for the total amount of the bonuses earned during the period earned. For the three and nine months ended September 30, 2017 , we recorded $193,000 and $943,000 of expense related to the 2017 incentive bonus plan as the performance conditions were achieved. Of the expense recorded for the three months ended September 30, 2017 , $153,000 is included in research and development expenses and $40,000 is included in general and administrative expenses. Of the expense recorded for the nine months ended September 30, 2017 , $584,000 is included in research and development expenses and $359,000 is included in general and administrative expenses. There was no expense for the period ended September 30, 2018 in connection with this program. 2017 Non-executive Bonus Program Effective July 1, 2017 , our non-executive employees participated in the 2017 Non-executive Bonus Program. The program provided for the award of up to 300,000 restricted stock units to be awarded to non-executive employees and consultants based upon the achievement of certain performance conditions before the end of the year. Vesting of the restricted stock units were subject to continued service over the vesting period. Based on the achievement of performance conditions, 180,528 restricted stock units were granted on January 25, 2018 at an aggregate grant date fair value of $1.1 million . The awards vest in four tranches with 25% of the shares vesting on each April 1, 2018, 2019, 2020 and 2021. For the three and nine months ended September 30, 2018 , we recorded $77,000 and $242,000 of stock compensation expense, respectively, related to the 2017 Non-executive Bonus Program. Additionally, upon grant we released the accrual of $436,000 which had been recorded as of December 31, 2017 related to performance under this program. Of the expense recorded for the three months ended September 30, 2018 , $62,000 and $15,000 is included in research and development expenses and general and administrative expenses, respectively. Of the expense recorded for the nine months ended September 30, 2018 , $195,000 and $47,000 is included in research and development expenses and general and administrative expenses, respectively. There was no expense recorded for the three and nine months ended September 30, 2017 as the achievement of the performance conditions were not probable. 2018 Incentive Bonus Program During 2018, our employees and executives, exclusive of the CEO, are participating in the 2018 Incentive Bonus Program. The program provides for the award of quarterly and annual bonuses to our employees and executive officers if certain performance goals, based on company-wide billings, expenses and certain other individual non-monetary targets, are attained in quarterly and annual performance periods during our 2018 fiscal year. The awards contain a combination of service conditions and performance conditions based on the achievement of specified performance thresholds. The awards are based on each individual’s annual salary multiplied by a bonus multiplier percentage which has been determined by our compensation committee. The plan also allows for additional discretionary awards to non-executive employees up to 10% of the total base salaries of non-executive employees. The bonuses will be paid in the form of cash, stock options, restricted stock, or a combination thereof. The number of shares underlying equity awards granted to each employee will be determined based on the performance bonus amount to be paid in equity, divided by our closing stock price on the grant date. We recognized compensation expense for the total amount of the bonuses earned during the period earned. For the three and nine months ended September 30, 2018, we recorded a total of $408,000 and $1.2 million, respectively, of expense related to the 2018 incentive bonus plan as the performance conditions were either achieved or in the case of the annual awards, are expected to be achieved. Included in the expense for 2018 was $919,000 related to quarterly awards and $292,000 related to the annual awards. The quarterly awards for the first and second quarters were issued in the form of restricted stock units in May 2018 and August 2018, respectively, and were vested in full during the month of grant. The quarterly award for the third quarter will be issued in the form of restricted stock units to be granted and vested in November 2018. We record an accrual for the annual component of the bonus program as the annual award will not be issued until after the year has ended. Of the expense recorded for the three months ended September 30, 2018, $269,000 is included in research and development expenses and $139,000 is included in general and administrative expenses. Of the expense recorded for the nine months ended September 30, 2018, $770,000 is included in research and development expenses and $441,000 is included in general and administrative expenses. There was no expense for the period ended September 30, 2017 in connection with this program as the program was not in place at that time. As of September 30, 2018, there was $608,000 included in accrued salaries and payroll related expenses related to the 2018 Incentive Bonus Program. 2018 CEO Incentive Bonus Program During 2018, our CEO is participating in the 2018 CEO Incentive Bonus Program. The program provides for the award of an annual bonus to our CEO if certain performance goals, based on company-wide billings and expenses are attained in the annual performance period during our 2018 fiscal year. Additionally, the annual bonus is subject to the achievement of certain stock price thresholds for the 10 trading days ending on December 19, 2018. We recognize compensation expense for the total amount of the bonus earned during the period earned. For the three months and nine months ended September 30, 2018 , we recorded compensation expense of $14,000 and $42,000 , respectively, as certain of the achievements of the performance conditions were considered probable. The expense was included in general and administrative expenses. As of September 30, 2018, there was $42,000 included in accrued salaries and payroll related expenses related to the 2018 CEO Incentive Bonus Program. Total equity-based compensation costs recorded in the condensed consolidated statements of operations is allocated as follows: Three Months Ended September 30, 2017 Three Months Ended September 30, 2018 Nine Months Ended September 30, 2017 Nine Months Ended September 30, 2018 Research and development Employees $ 304,000 $ 672,000 $ 839,000 $ 1,975,000 Non-employees 20,000 14,000 61,000 58,000 Total research and development 324,000 686,000 900,000 2,033,000 General and administrative Employees and directors 314,000 337,000 998,000 1,471,000 Non-employees 28,000 345,000 126,000 454,000 Total general and administrative 342,000 682,000 1,124,000 1,925,000 Total equity-based compensation $ 666,000 $ 1,368,000 $ 2,024,000 $ 3,958,000

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax for the three months ended September 30, 2017 and 2018 was a benefit of $16,000 and $11,000 , respectively. Income tax for the nine months ended September 30, 2017 and 2018 was a benefit of $40,000 and $19,000 , respectively. The effective tax rate for the three months ended September 30, 2017 and 2018 and nine months ended September 30, 2017 and 2018 differed from the statutory rate primarily due to the valuation allowance recorded against the Company’s deferred tax assets.

RELATED PARTY TRANSACTION

RELATED PARTY TRANSACTION	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	RELATED PARTY TRANSACTIONS In August 2016, we entered into a consulting agreement with a member of our board of directors. Under the agreement, the board member would provide engineering design and fabrication advisory services for an hourly rate, with total payments not to exceed $120,000 during any twelve-month period. During the nine months ended September 30, 2017, we incurred expenses of $26,000 in connection with the consulting agreement. The agreement was terminated effective April 1, 2017. There was no expense for the three and nine months ended September 30, 2018 .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Commitments —In October 2013, we signed a lease for office space for our corporate headquarters and moved in during the first quarter of 2014. The lease, as amended, had an expiration of July 31, 2018. In May 2018, we entered into an agreement with the landlord to extend the lease for one month, through August 2018 with no change to the amount of rent or other payments due under the lease. Subsequently, we negotiated with the landlord for an extension through September 2018 when we moved to our new location. In May 2018, we signed a lease for our current corporate headquarters. The lease provides for an initial space of 16,682 square feet (the "initial" premises) beginning in September 2018 and an additional 10,355 square feet (the "expansion" premises) beginning January 2019. The lease term is 72 months and expires on August 31, 2024. The agreement allows for one option to renew for an additional five years. Base rent on the initial premises is abated for September and October of 2018 and is $19,500 per month from November 1, 2018 to July 31, 2019. Base rent on the initial premises increases to $25,774 per month as of August 1, 2019 and then escalates by 3% on each anniversary date thereafter. Base rent on the expansion premises is $7,767 per month from January 1, 2019 through June 30, 2019 with an increase to $15,533 for the month of July 2019 and an increase to $15,998 per month effective August 1, 2019 with 3% escalations on each anniversary date thereafter. We are also required to pay our proportionate share of operating expenses and utilities which are estimated to initially be $11,177 per month for the 2018 period utilizing only the initial premises. Our share of operating expenses and utilities will increase once we occupy the expansion premises and will likely fluctuate in the future. Per the terms of the lease we are also required to maintain as a security deposit $50,000 in cash and a letter of credit in favor of the lessor. The initial amount of the letter of credit is $200,000 with a step-down of $50,000 at each anniversary date if there have been no monetary defaults. The letter of credit is secured by a pledge in favor of the issuing bank of a $211,000 mutual fund account which is classified as restricted cash on our balance sheet as of September 30, 2018. In November 2013, we signed a lease for our satellite development office in Burlingame, CA. The lease had a two -year term, and rental costs of approximately $4,000 per month. In May 2015, we renewed the lease for a one year period expiring November 30, 2016 with rental costs of $5,000 per month. Effective December 16, 2016 , we signed a new lease of 5,248 square feet of office space within the same building in Burlingame, California commencing February 2017. The lease has a five year term, and rental costs of approximately $17,000 per month. Rent expense related to our facilities and equipment for the three months ended September 30, 2017 and 2018 was $127,000 and $200,000 , respectively, and for the nine months ended September 30, 2017 and 2018 was $339,000 and $484,000 , respectively. Legal Proceedings — W e are occasionally involved in legal proceedings and other matters arising from the normal course of business. On September 24, 2015, a purported shareholder derivative action was filed in the United States District Court for the Central District of California. The plaintiff alleged that certain of our officers and directors breached their fiduciary duties to us, violated federal securities laws and exposed us to possible financial liability. On August 15, 2018, the court granted final approval of a settlement which fully resolved plaintiffs' claims and provided for a release of all claims asserted in the derivative action, bringing the litigation to a close. We are not party to any other legal proceedings. We may, from time to time, be party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of any future matters could materially affect our future financial position, results of operations or cash flows. Legal fees and other costs associated with legal proceedings are expensed as incurred. We assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. We evaluate developments in legal proceedings and other matters on a quarterly basis. As of September 30, 2017 and 2018 , there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the three and nine months ended September 30, 2017 and 2018 , respectively, with respect to litigation or loss contingencies.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates —The accompanying condensed consolidated financial statements at September 30, 2018 and for the three and nine months ended September 30, 2017 and 2018 are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Prior period figures have been reclassified, wherever necessary, to conform to current presentation. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2017 have been derived from our audited consolidated financial statements as of that date. The condensed consolidated financial statements included herein have been prepared by us pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017 . Our operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been include
Consolidation	Consolidation —The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR Trade, S.A. All significant intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR Trade S.A., our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held.
Restricted Cash	Restricted Cash —Restricted cash at December 31, 2017 consisted of a $100,000 certificate of deposit with a financial institution, which served as collateral for our corporate credit cards. During the nine months ended September 30, 2018 we terminated the corporate credit card program for which the certificate of deposit was held and thus the restriction was lifted.
Investments	Investments —Securities held-to-maturity: Management determines the appropriate classification of securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in interest and investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in net securities gains (losses). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in net securities gains (losses). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income. During 2017 , we invested in commercial papers and certificates of deposit that were classified as held-to-maturity. Additionally, we maintained money market fund balances that were classified as cash and cash equivalents. As of September 30, 2017 , all of the investments had matured and there were no investments classified as held-to-maturity. We recorded investment income of $14,000 and $39,000 for the three and nine months ended September 30, 2017, respectively, associated with the investments. During 2018 , we invested in U.S. Treasury bills, commercial papers and a certificate of deposit that were classified as investments held-to-maturity. Additionally, we maintained money market fund balances that were classified as cash and cash equivalents. As of September 30, 2018 , the amortized cost value and fair value are $8.9 million with zero unrealized gain or loss. U.S. Treasury bills totaling $25.0 million matured in April 2018 and certain commercial papers totaling $14.7 million matured during the nine months ended September 30, 2018. Remaining commercial papers totaling $8.8 million mature in January 2019, and the certificate of deposit for $100,000 matures in January 2019 .
Fair Value of Financial Instruments	Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exit price notion, or price that would be received for an asset or paid to transfer a liability, in an orderly transaction between the market participants at the measurement date. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.
Accounts Receivable	Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact ability to collect the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. There was no allowance for doubtful accounts at December 31, 2017 and September 30, 2018 .
Property and Equipment	Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to six years. Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Intangible Assets, net	Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2017 and September 30, 2018 , intangible assets, net, includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or are abandoned as we no longer plan to pursue them. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses.
Goodwill	Goodwill— At December 31, 2017 and September 30, 2018 , goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Revenue Recognition	Revenue Recognition —As of January 1, 2018, we recognize revenue in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers. Revenue is recognized upon the transfer of control of promised goods or services to the customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of fees received in connection with filter design projects with customers. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue over the course of the design development phase as our customers are able to benefit from our design services as they are provided, primarily by marketing the in-process design to their customers. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. In most cases, our design services are performed over a period of six to twelve months. Contracts generally include upfront non-refundable fees, intended to support our initial engineering product development efforts, as well as milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. At contract inception, we assess the likelihood of achieving milestones to estimate the total consideration we believe we will receive for our services. Our design service contracts also include a functional license over the completed design, which enables our customer to use our design in products marketed to their customers. We also earn royalties for each product shipped by our customer that incorporates one of our designs. Royalty fees are recorded upon shipment by our customer, and payment is generally due within 30 days. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense.
Research and Development	Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development .
Operating Leases	Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We recognize rent expense under such leases on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the lease term.
Stock-Based Compensation	Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered.
Earnings Per Share, or EPS	Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards.
Income Taxes	Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2017 and September 30, 2018 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the three and nine months ended September 30, 2017 and 2018. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome would be unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows.
Foreign Currency Remeasurement	Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive loss in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive loss in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases , which provides clarity to certain narrow aspects of the new standard and ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides an optional transition method for adopting the new leases guidance that eliminates comparative period reporting under the new guidance in the year of adoption. . The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We plan to adopt the standard, as well as the practical expedients included therein, as of January 1, 2019. We have reviewed our leases and other agreements in order to determine the effects of the new guidance on our consolidated financial statements. We have determined that we have two facility leases that meet the criteria for recognition of lease assets and lease liabilities on the balance sheet under the new guidance. We are not party to any leases for which we are the lessor. We believe the adoption will cause us to recognize a significant right-of-use asset as well as the related lease liability in our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements. Compensation-Stock Compensation— In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting , which intends to align the accounting of share-based payment awards issued to employees and non-employees. This update will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. Early adoption is permitted. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements as we have very few share-based payment arrangements with non-employees.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Nine Months Ended September 30, 2017 2018 Common stock warrants 6,202,147 3,385,100 Common stock options 908,560 1,234,967 Non-vested restricted stock unit awards 1,401,693 2,071,299 Total shares excluded from net loss per share attributable to common stockholders 8,512,400 6,691,366

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The cumulative effect of the changes made to our condensed consolidated balance sheet as of January 1, 2018 for the adoption of the new standard was as follows: BALANCE SHEET Balance at December 31, 2017 Adjustments Due to ASC 606 Balance at January 1, 2018 ASSETS Prepaid expenses and other current assets $ 536,000 $ 67,000 $ 603,000 LIABILITIES AND STOCKHOLDERS' EQUITY Deferred Revenue, current $ 143,000 $ 3,000 $ 146,000 Retained Earnings $ (67,812,000 ) $ 64,000 $ (67,748,000 ) The following table summarizes the impact of the adoption on our Condensed Consolidated Balance Sheet and Condensed Consolidated Statement of Comprehensive Loss as of and for the periods ended September 30, 2018: September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Increase/(Decrease) BALANCE SHEET ASSETS Prepaid expenses and other current assets $ 397,000 $ 394,000 $ 3,000 LIABILITIES AND STOCKHOLDERS' EQUITY Deferred revenue, current $ 187,000 $ 160,000 $ 27,000 Accumulated deficit $ (85,691,000 ) $ (85,667,000 ) $ (24,000 ) Three Months Ended September 30, 2018 As Reported Activity Without Adoption of ASC 606 Effect of Change Increase/(Decrease) STATEMENT OF COMPREHENSIVE LOSS Revenue $ 115,000 $ 155,000 $ (40,000 ) Net loss $ (6,275,000 ) $ (6,235,000 ) $ 40,000 Nine Months Ended September 30, 2018 As Reported Activity Without Adoption of ASC 606 Effect of Change Increase/(Decrease) STATEMENT OF COMPREHENSIVE LOSS Revenue $ 396,000 $ 484,000 $ (88,000 ) Net loss $ (17,943,000 ) $ (17,855,000 ) $ 88,000
Disaggregation of Revenue	Summary of changes in contract assets and liabilities for the period from January 1, 2018 to September 30, 2018: Contract asset Contract asset, January 1, 2018 $ 67,000 Contract assets at beginning of year transferred to accounts receivable (43,000 ) Reversal of contract assets due to changes in transaction price (24,000 ) Contract assets recorded on contracts during the period 3,000 Contract asset, September 30, 2018 $ 3,000 Contract liability Contract liability, January 1, 2018 $ 146,000 Recognition of revenue included in beginning of year contract liability (92,000 ) Contract liability, net of revenue recognized on contracts during the period 132,000 Foreign currency translation 1,000 Contract liability, September 30, 2018 $ 187,000
Revenue from External Customers by Geographic Areas	The following table presents our disaggregated revenue by region and source: Three Months Ended September 30, Nine Months Ended September 30, 2017 2018 2017 2018 Revenue by geographic region: United States $ 89,000 $ 96,000 $ 415,000 $ 338,000 Switzerland 17,000 19,000 67,000 58,000 Total revenue $ 106,000 $ 115,000 $ 482,000 $ 396,000 Revenue by source: Design services $ 99,000 $ 85,000 $ 465,000 $ 276,000 Royalties 7,000 30,000 17,000 120,000 Total revenue $ 106,000 $ 115,000 $ 482,000 $ 396,000

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrant activity	A roll-forward of warrant share activity from January 1, 2017 to September 30, 2017 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2017 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2017 Bridge Warrants 249,999 — — 249,999 Consulting Warrants 98,000 — (41,889 ) (1) 56,111 Financing Warrants 78,186 — — 78,186 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 48,000 — (42,000 ) (2) 6,000 Private Placement Warrants - 2016 1,995,124 — (89,281 ) (3) 1,905,843 Underwriting Warrants- Public Offering 2016 135,750 — — 135,750 Private Placement Warrants - February 2017 — 1,626,898 — 1,626,898 Private Placement Warrants - September 2017 — 1,832,860 — 1,832,860 2,915,559 3,459,758 (173,170 ) 6,202,147 (1) During the nine months ended September 30, 2017, there were 41,889 common stock warrants that were exercised through cashless exercises which resulted in 41,800 shares being issued. (2) During the nine months ended September 30, 2017, 42,000 warrants expired. (3) During the nine months ended September 30, 2017, there were 89,281 common stock warrants that were exercised through cashless exercises which resulted in 37,031 shares being issued. A roll-forward of warrant share activity from January 1, 2018 to September 30, 2018 is shown in the following table: Issued and Outstanding Warrants as of January 1, 2018 Warrants Issued Warrants Exercised/ Expired Issued and Outstanding Warrants as of September 30, 2018 Bridge Warrants 249,999 — (249,999 ) (1) — Consulting Warrants 12,223 — (5,556 ) (2) 6,667 Financing Warrants 62,530 — — 62,530 Underwriting Warrants 310,500 — — 310,500 IR Consulting Warrants 6,000 — (6,000 ) (3) — Private Placement Warrants - 2016 891,063 — (73,000 ) (4) 818,063 Underwriting Warrants - Public Offering 2016 122,175 — — 122,175 Private Placement Warrants - September 2017 1,976,919 — (10,600 ) (5) 1,966,319 Placement Agent Warrants 98,846 — — 98,846 3,730,255 — (345,155 ) 3,385,100 (1) During the nine months ended September 30, 2018 , there were 249,999 warrants that were exchanged for 242,913 shares of common stock in an exchange transaction where the warrant holders exchanged the warrants for the same number of shares they would have been entitled to in a cashless exercise. (2) During the nine months ended September 30, 2018 , there were 5,556 warrants that were exercised through a cashless exercise which netted 5,542 shares of common stock being issued. (3) During the nine months ended September 30, 2018 , 6,000 warrants expired. (4) During the nine months ended September 30, 2018 , there were 73,000 warrants exercised for cash. (5) During the nine months ended September 30, 2018 , there were 10,600 warrants exercised for cash.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of fair values of stock options granted, estimated using Black-Scholes option valuation model assumptions	We estimated the fair value of stock options awarded during the nine months ended September 30, 2017 and 2018 using the Black-Scholes option valuation model. The fair values of stock options granted for the periods were estimated using the following assumptions: Stock Option Grants Awarded During the Nine Months Ended September 30, 2017 Stock Option Grants Awarded During the Nine Months Ended September 30, 2018 Stock Price $4.36 to $4.68 $4.12 to $5.96 Dividend Yield 0.00% 0.00% Expected Volatility 60% 70% Risk-free interest rate 1.95% - 2.14% 2.50% - 2.98% Expected Life 7 years 7 years
Summary of stock option activity	The following is a summary of our stock option activity during the nine months ended September 30, 2018 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2018 1,082,490 $ 4.87 $ 3.00 8.38 Granted 227,500 4.77 3.24 9.31 Exercised (4,692 ) 2.91 1.75 — Canceled / Forfeited (70,331 ) 4.73 2.89 — Outstanding, September 30, 2018 1,234,967 $ 4.86 $ 3.06 7.95 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2018 704,303 $ 5.08 $ 3.17 8.15 Vested 114,591 4.76 2.90 7.54 Exercised (4,692 ) 2.91 1.75 — Canceled / Forfeited (17,057 ) 4.72 2.84 — Exercisable, September 30, 2018 797,145 $ 5.05 $ 3.15 7.43
Schedule of information related to stock options outstanding and exercisable	The following table presents information related to stock options outstanding and exercisable at September 30, 2018 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.93 – $2.00 146,183 7.34 90,323 $3.83 – $4.92 646,984 8.63 370,907 $5.01 – $6.00 281,500 6.04 207,455 $6.18 – $7.20 70,000 6.15 53,753 $7.54 – $7.80 67,800 6.32 54,540 $8.06 – $12.98 22,500 6.30 20,167 1,234,967 7.43 797,145
Schedule of restricted stock unit activity	A summary of restricted stock unit activity for the nine months ended September 30, 2018 is as follows: Number of Restricted Share Units Weighted- Average Grant-Date Fair Value Per Share Outstanding at January 1, 2018 1,476,858 $ 4.96 Granted 1,379,905 4.81 Vested (621,263 ) 4.93 Forfeited (164,201 ) 5.16 Outstanding at September 30, 2018 2,071,299 $ 4.85
Schedule of stock-based compensation	Total equity-based compensation costs recorded in the condensed consolidated statements of operations is allocated as follows: Three Months Ended September 30, 2017 Three Months Ended September 30, 2018 Nine Months Ended September 30, 2017 Nine Months Ended September 30, 2018 Research and development Employees $ 304,000 $ 672,000 $ 839,000 $ 1,975,000 Non-employees 20,000 14,000 61,000 58,000 Total research and development 324,000 686,000 900,000 2,033,000 General and administrative Employees and directors 314,000 337,000 998,000 1,471,000 Non-employees 28,000 345,000 126,000 454,000 Total general and administrative 342,000 682,000 1,124,000 1,925,000 Total equity-based compensation $ 666,000 $ 1,368,000 $ 2,024,000 $ 3,958,000

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Liquidity and Capital Resources) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 85,691		$ 67,748	$ 67,812
Cash and cash equivalents	17,470	$ 13,530		19,524
Investments	8,884			$ 0
Proceeds from sale of common stock	21,190	$ 0
Substantial doubt about going concern, management's evaluation, cash used in the period	$ 14,600

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)financial_institution	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)financial_institution	Sep. 30, 2017USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)
Concentration Risks, Types, No Concentration Percentage
Number of financial institutions where the Company holds checking deposits | financial_institution	1		1
Restricted Cash [Abstract]
Restricted cash, certificate of deposit	$ 0	$ 100,000	$ 0	$ 100,000		$ 100,000
Restricted cash, pledged mutual fund	211,000		211,000			0
Investments
Investment income		14,000		39,000
Held-to-maturity Securities, Fair Value	8,900,000		8,900,000
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0		0
Investments held-to-maturity	8,884,000		8,884,000			0
Intangible Assets, Net
Impairment of intangible assets	39,000		87,000
Revenue Related to Research and Development [Abstract]
Revenues	115,000	106,000	396,000	$ 482,000
Deferred revenue	187,000		187,000		$ 146,000	143,000
Income Taxes
Income tax penalties and interest accrued	0		$ 0			$ 0
Income tax penalties and interest expense	0	$ 0
Minimum
Property and Equipment
Useful life (in years)			3 years
Maximum
Property and Equipment
Useful life (in years)			6 years
US Treasury Bills, Maturing April 2018
Investments
Investments held-to-maturity	25,000,000		$ 25,000,000
Commercial Paper, Maturing June 2018
Investments
Investments held-to-maturity	14,700,000		14,700,000
Commercial Paper, Maturing January 2019
Investments
Investments held-to-maturity	8,800,000		8,800,000
Certificates of Deposit | Debt Securities, Maturing January 2019
Investments
Investments held-to-maturity	100,000		100,000
Certificates of Deposit | Foreign Debt Securities
Investments
Investment income	$ 177,000		$ 323,000

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Anti-Dilutive Shares Excluded from Calculation or EPS) (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	6,691,366	8,512,400
Common stock warrants
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	3,385,100	6,202,147
Common stock options
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	1,234,967	908,560
Non-vested restricted stock unit awards
Earnings Per Share, or EPS
Number of anti-dilutive shares excluded from the calculation of diluted net loss per share attributable to common stockholders	2,071,299	1,401,693

REVENUE RECOGNITION - Schedule

REVENUE RECOGNITION - Schedule of Effect of New Accounting Pronouncements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenues	$ 115,000	$ 106,000	$ 396,000	$ 482,000
Prepaid expenses and other current assets	397,000		397,000		$ 603,000	$ 536,000
Deferred revenue	187,000		187,000		146,000	143,000
Accumulated deficit	(85,691,000)		(85,691,000)		$ (67,748,000)	(67,812,000)
Net loss	(6,275,000)	$ (4,184,000)	(17,943,000)	$ (13,341,000)
Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenues	155,000		484,000
Prepaid expenses and other current assets	394,000		394,000			536,000
Deferred revenue	160,000		160,000			143,000
Accumulated deficit	(85,667,000)		(85,667,000)			(67,812,000)
Net loss	(6,235,000)		(17,855,000)
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenues	(40,000)		(88,000)
Prepaid expenses and other current assets	3,000		3,000			67,000
Deferred revenue	27,000		27,000			3,000
Accumulated deficit	(24,000)		(24,000)			$ 64,000
Net loss	$ 40,000		$ 88,000

REVENUE RECOGNITION - Schedul_2

REVENUE RECOGNITION - Schedule of Changes in Contract Asset and Liability Balances (Details)	9 Months Ended
	Sep. 30, 2018USD ($)
Contract asset
Contract asset, January 1, 2018	$ 67,000
Contract assets at beginning of year transferred to accounts receivable	(43,000)
Reversal of contract assets due to changes in transaction price	(24,000)
Contract assets recorded on contracts during the period	3,000
Contract asset, September 30, 2018	3,000
Contract liability
Contract liability, January 1, 2018	146,000
Recognition of revenue included in beginning of year contract liability	(92,000)
Contract liability, net of revenue recognized on contracts during the period	132,000
Foreign currency translation	1,000
Contract liability, September 30, 2018	$ 187,000

REVENUE RECOGNITION - Schedul_3

REVENUE RECOGNITION - Schedule of Revenue from Customer by Geographic Area and Source (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
REVENUES	$ 115	$ 106	$ 396	$ 482
Design services
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
REVENUES	85	99	276	465
Royalties
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
REVENUES	30	7	120	17
United States
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
REVENUES	96	89	338	415
Switzerland
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
REVENUES	$ 19	$ 17	$ 58	$ 67

WARRANTS (Narrative) (Details)

WARRANTS (Narrative) (Details) $ / shares in Units, $ in Thousands

Dec. 19, 2017USD ($)$ / sharesshares

Dec. 18, 2017USD ($)$ / shares

Sep. 28, 2017USD ($)$ / sharesshares

Sep. 30, 2017USD ($)$ / shares

Feb. 28, 2017USD ($)$ / sharesshares

Oct. 31, 2017$ / sharesshares

Sep. 30, 2018USD ($)

Sep. 30, 2017USD ($)$ / shares

Dec. 31, 2017USD ($)

Oct. 02, 2017shares

Jun. 17, 2013$ / sharesshares

Jan. 31, 2013$ / shares

Warrant liabilities

Fair value of common stock issued

$ 27

$ 20

Proceeds from exercise of warrants

260

$ 0

Placement Agent

Warrant liabilities

Warrant fair value

$ 174

Warrant share price (in dollars per share) | $ / shares

$ 4.85

Bridge Warrants | Founders

Warrant liabilities

Warrants to purchase shares of common stock (in unit/shares) | shares

249,999

Exercise price (in dollars per unit/share) | $ / shares

$ 0.20

Fair value of the warrants

1,600

Fair value of common stock issued

1,600

Private Placement Warrants, February 2017, After Modifications

Warrant liabilities

Warrant fair value

$ 6,700

Underwriting Warrant

Warrant liabilities

New shares issued (in shares) | shares

1,976,919

Underwriting Warrant | Placement Agent

Warrant liabilities

New shares issued (in shares) | shares

98,846

Private Placement Warrants, February 2017

Warrant liabilities

Warrant fair value

$ 13,400

$ 4,100

Warrant share price (in dollars per share) | $ / shares

$ 8.18

$ 8.18

Fair value adjustment expense

$ 4,100

Class of warrant or right, inducement expense

6,700

Induced conversion of convertible debt expense

2,600

Proceeds from exercise of warrants

$ 6,700

Private Placement Warrants, February 2017 | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 8.25

Private Placement Warrants, September 2017

Warrant liabilities

Warrant fair value

$ 3,600

Capital Units | Private Placement Warrants - 2016 | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 8.25

Capital Units | Private Placement Warrants, September 2017 | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 4.85

Common stock warrants | Investor

Warrant liabilities

Warrant term, period end after closing

30 months

Common stock warrants | Placement Agent

Warrant liabilities

Warrant term, period start after closing

6 months

Private Placement Warrants - 2016 | Private Placement Warrants - 2016

Warrant liabilities

Warrants to purchase shares of common stock (in unit/shares) | shares

1,626,898

Private Placement Warrants - 2016 | Private Placement Warrants, February 2017

Warrant liabilities

Warrants to purchase shares of common stock (in unit/shares) | shares

1,626,898

Private Placement Warrants - 2016 | Private Placement Warrants, February 2017 | Investor

Warrant liabilities

New shares issued (in shares) | shares

1,626,898

Private Placement Warrants - 2016 | Private Placement Warrants, September 2017

Warrant liabilities

Warrants to purchase shares of common stock (in unit/shares) | shares

1,745,581

1,976,919

231,338

Warrant term, period start after closing

6 months

Warrant term, period end after closing

36 months

Private Placement Warrants - 2016 | Capital Units | Private Placement Warrants - 2016 | Investor

Warrant liabilities

New shares issued (in shares) | shares

1,626,898

Private Placement Warrants - 2016 | Capital Units | Private Placement Warrants, September 2017 | Investors, Executives and Board Members

Warrant liabilities

New shares issued (in shares) | shares

1,976,919

Private Placement, Offering One | Placement Agent

Warrant liabilities

Partners' capital account, units, sold in private placement (in warrants) | shares

87,279

Private Placement, Offering Two | Placement Agent

Warrant liabilities

Partners' capital account, units, sold in private placement (in warrants) | shares

11,567

Investor Relations | Consulting Warrant Issued In August2014

Warrant liabilities

Exercise price (in dollars per unit/share) | $ / shares

$ 0.40

Investor Relations | Private Placement Warrants - 2016

Warrant liabilities

Warrant fair value

$ 2,084

Warrant share price (in dollars per share) | $ / shares

$ 4.91

Minimum | Underwriting Warrant

Warrant liabilities

Warrant share price (in dollars per share) | $ / shares

$ 4.49

Minimum | Private Placement Warrants, September 2017

Warrant liabilities

Warrant share price (in dollars per share) | $ / shares

$ 4.49

$ 4.49

Maximum | Underwriting Warrant

Warrant liabilities

Warrant share price (in dollars per share) | $ / shares

$ 4.69

Maximum | Private Placement Warrants, September 2017

Warrant liabilities

Warrant share price (in dollars per share) | $ / shares

$ 4.69

$ 4.69

Common Units Class B | Founders

Warrant liabilities

Warrants to purchase shares of common stock (in unit/shares) | shares

124,998

General and administrative expenses | Bridge Warrants | Founders

Warrant liabilities

Fair value adjustment expense

$ 2

Measurement Input, Expected Term | Private Placement Warrants, February 2017

Warrant liabilities

Warrants and Rights Outstanding, Term

1 year 8 months 1 day

Measurement Input, Expected Term | Common Stock | Private Placement Warrants - 2016

Warrant liabilities

Warrants and Rights Outstanding, Term

1 day

Measurement Input, Expected Term | Common Stock | Underwriting Warrant

Warrant liabilities

Warrants and Rights Outstanding, Term

3 years

Measurement Input, Expected Term | Investor Relations | Private Placement Warrants - 2016

Warrant liabilities

Warrants and Rights Outstanding, Term

3 years

Measurement Input, Price Volatility | Underwriting Warrant

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.60

Measurement Input, Price Volatility | Private Placement Warrants, February 2017

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.10

Measurement Input, Price Volatility | Investor Relations | Private Placement Warrants - 2016

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.60

Measurement Input, Expected Dividend Rate | Private Placement Warrants, February 2017

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.0125

Measurement Input, Expected Dividend Rate | Common Stock | Private Placement Warrants - 2016

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0

0.0178

Measurement Input, Expected Dividend Rate | Investor Relations | Private Placement Warrants - 2016

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0

Measurement Input, Expected Dividend Rate | Minimum | Underwriting Warrant

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.0159

Measurement Input, Expected Dividend Rate | Minimum | Private Placement Warrants, September 2017

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.0159

0.0159

Measurement Input, Expected Dividend Rate | Maximum | Underwriting Warrant

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.0163

Measurement Input, Expected Dividend Rate | Maximum | Private Placement Warrants, September 2017

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.0163

0.0163

Measurement Input, Risk Free Interest Rate [Member] | Investor Relations | Private Placement Warrants - 2016

Warrant liabilities

Warrants and Rights Outstanding, Measurement Input

0.0150

WARRANTS (Warrant Share Activit

WARRANTS (Warrant Share Activity) (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	3,730,255	2,915,559
Warrants Issued (in warrants)	0	3,459,758
Warrants Exercised/Expired (in warrants)	(345,155)	(173,170)
Balance at the end of the period (in warrants)	3,385,100	6,202,147
Bridge Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	249,999	249,999
Warrants Issued (in warrants)	0	0
Warrants Exercised/Expired (in warrants)	(249,999)	0
Balance at the end of the period (in warrants)	0	249,999
Consulting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	12,223	98,000
Warrants Issued (in warrants)	0	0
Warrants Exercised/Expired (in warrants)	(5,556)	(41,889)
Balance at the end of the period (in warrants)	6,667	56,111
Exercise of warrants (in warrants)	5,542	41,800
Financing Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	62,530	78,186
Warrants Issued (in warrants)	0	0
Warrants Exercised/Expired (in warrants)	0	0
Balance at the end of the period (in warrants)	62,530	78,186
Underwriting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	310,500	310,500
Warrants Issued (in warrants)	0	0
Warrants Exercised/Expired (in warrants)	0	0
Balance at the end of the period (in warrants)	310,500	310,500
IR Consulting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	6,000	48,000
Warrants Issued (in warrants)	0	0
Warrants Exercised/Expired (in warrants)	(6,000)	(42,000)
Balance at the end of the period (in warrants)	0	6,000
Private Placement Warrants - 2016
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	891,063
Warrants Issued (in warrants)	0
Warrants Exercised/Expired (in warrants)	(73,000)
Balance at the end of the period (in warrants)	818,063
Underwriting Warrants - Public Offering 2016
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	98,846	0
Warrants Issued (in warrants)		1,626,898
Warrants Exercised/Expired (in warrants)		0
Balance at the end of the period (in warrants)	98,846	1,626,898
Private Placement Warrants - 2016
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	122,175	1,995,124
Warrants Issued (in warrants)	0	0
Warrants Exercised/Expired (in warrants)	0	(89,281)
Balance at the end of the period (in warrants)	122,175	1,905,843
Exercise of warrants (in warrants)	242,913	37,031
Private Placement Warrants - September 2017
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)	1,976,919	135,750
Warrants Issued (in warrants)	0	0
Warrants Exercised/Expired (in warrants)	(10,600)	0
Balance at the end of the period (in warrants)	1,966,319	135,750
Private Placement Warrants, September 2017
Roll forward of warrant activity
Balance at the beginning of the period (in warrants)		0
Warrants Issued (in warrants)		1,832,860
Warrants Exercised/Expired (in warrants)		0
Balance at the end of the period (in warrants)		1,832,860

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 06, 2018	Mar. 27, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Class of Stock [Line Items]
Common stock, shares authorized			47,000,000		47,000,000
Net proceeds from the sale of common stock from private placement offering			$ 0	$ 15,025
Net proceeds from units issued in the period			$ 21,190
Preferred stock, shares authorized			3,000,000		3,000,000
Common Stock
Class of Stock [Line Items]
New shares issued (in shares)		5,714,286	6,571,428
Share price (in dollars per share)		$ 3.50
Net proceeds from the sale of common stock from private placement offering		$ 20,000
Net proceeds from units issued in the period		$ 18,400	$ 7
Over-Allotment Option | Common Stock
Class of Stock [Line Items]
New shares issued (in shares)	857,142
Share price (in dollars per share)	$ 3.50
Net proceeds from the sale of common stock from private placement offering	$ 3,000
Net proceeds from units issued in the period	$ 2,800

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Details) $ / shares in Units, $ in Thousands	Sep. 30, 2019	Jan. 25, 2018USD ($)shares	Aug. 08, 2016	Jun. 30, 2017shares	Jan. 31, 2017shares	Aug. 31, 2016shares	Jun. 30, 2016shares	Sep. 30, 2018USD ($)quarter$ / sharesshares	Sep. 30, 2017USD ($)quartershares	Sep. 30, 2018USD ($)quarter$ / sharesshares	Sep. 30, 2017USD ($)quarter$ / sharesshares	Dec. 31, 2017USD ($)	Jul. 01, 2017shares	Jan. 31, 2014shares
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares								110,000	131,500	227,500	299,880
Vested (in shares) | shares										114,591	125,880
Unrecognized compensation expense related to unvested employee stock option								$ 1,200		$ 1,200
Options outstanding, aggregate intrinsic value								300		300
Options vested, aggregate intrinsic value								$ 190		$ 190
Share price (in dollars per share) | $ / shares								$ 4.06		$ 4.06
Weighted average period										3 years
Granted (in dollars per share) | $ / shares										$ 4.77
Common stock options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share) | $ / shares											$ 4.36
Common stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per share) | $ / shares											$ 4.68
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								$ 1,200	$ 564	$ 3,300	$ 1,700
Unrecognized compensation expense related to unvested employee stock option								$ 6,900		$ 6,900
Weighted average period										2 years 3 months 26 days
Granted (in shares) | shares										1,379,905
Vested (in shares) | shares										621,263
Granted (in dollars per share) | $ / shares										$ 4.81
Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance bonus amount, percent of estimate								10.00%
2014 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock approved for issuance (in shares) | shares								5,950,000		5,950,000				1,400,000
Number of additional shares authorized (in shares) | shares				3,250,000			1,300,000
Employees and Consultants | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award										10 years
Aggregate grant date fair value of options granted								$ 345		$ 738
Employees | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share) | $ / shares										$ 4.12	$ 4.36
Exercise price range, upper limit (in dollars per share) | $ / shares										$ 5.96	$ 4.68
Term of award											10 years
Number of quarters over which awards vest, grant date subsequent to initial vesting | quarter								16		16
Aggregate grant date fair value of options granted									356		$ 802
Stock compensation								$ 125	100	$ 347	$ 332
Forfeitures rate										6.00%	6.00%
Consultants | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								2	2	$ 6	$ 7
Employees and directors | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Bonus percentage										10.00%
Non-executive employees | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Bonus percentage												10.00%
Non-executive employees | Non-executive Bonus Program 2017 | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock approved for issuance (in shares) | shares													300,000
Granted (in shares) | shares		180,528
Stock compensation								77		$ 242
Unrecognized compensation expense related to unvested employee stock option		$ 1,100
Award vesting rights, percent												25.00%
Accrued Bonuses												$ 436
Executives | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated vesting, number of shares impacted | shares					8,752
Option exercise period extended, number of shares impacted | shares					17,504
Plan modification, incremental compensation cost								0			19
Executives | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated vesting, number of shares impacted | shares					8,815
Plan modification, incremental compensation cost								0			36
Executives | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares						250,000
Award vesting rights, percent			50.00%
Executives | Performance Based Awards | Maximum | Forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percent	50.00%
Executives | 2015 Performance Plan | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share) | $ / shares										$ 5.06
Common Stock | 2017 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								0	0
Common Stock | Non-executive Bonus Program 2017 | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								0	0
Common Stock | 2018 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period												10 days
Stock compensation										$ 608	0
Common Stock | Employees and directors | 2018 Incentive Bonus Program | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								919		292
Common Stock | Employees and directors | 2018 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								408		1,200
Common Stock | Executives
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation										$ 0
Common Stock | Executives | 2015 Performance Plan | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period										1 year
Stock compensation									6	$ 18	19
Compensation cost not yet recognized								24		24
Common Stock | Executives | 2017 Incentive Bonus Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									193		943
Common Stock | Chief Executive Officer | 2018 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								14		42
Accrued Bonuses								42		42
Research and development expenses | Common Stock | 2017 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation									$ 153		584
Research and development expenses | Common Stock | Non-executive Bonus Program 2017 | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								62		195
Research and development expenses | Common Stock | 2018 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								269		770
General and administrative expenses | Common Stock | 2017 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation										40	$ 359
General and administrative expenses | Common Stock | Non-executive Bonus Program 2017 | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								15		47
General and administrative expenses | Common Stock | 2018 Incentive Bonus Program | Performance Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation								$ 139		$ 441
Nine days after grant date | Employees | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected to vest (in shares) | shares									91,500		91,500
Number of days after grant, expected vesting											9 days
Sixteen quarters after grant date | Employees | Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected to vest (in shares) | shares									82,500		82,500
Number of quarters over which awards vest, grant date subsequent to initial vesting | quarter									16		16

STOCK-BASED COMPENSATION (Estim

STOCK-BASED COMPENSATION (Estimated Fair Value of Stock Options) (Details) - Common stock options - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend Yield	0.00%	0.00%
Expected Volatility	60.00%	70.00%
Expected Life	7 years	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.50%	1.98%
Exercise price range, lower limit (in dollars per share)		$ 4.36
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.98%	2.14%
Exercise price range, upper limit (in dollars per share)		$ 4.68
Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share)	$ 4.12	4.36
Exercise price range, upper limit (in dollars per share)	$ 5.96	$ 4.68
Forfeitures rate	6.00%	6.00%

STOCK-BASED COMPENSATION (Stock

STOCK-BASED COMPENSATION (Stock Option Award Activity) (Details) - Common stock options - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2016
Number of Options outstanding
Outstanding at the beginning of the year (in shares)			1,082,490
Granted (in shares)	110,000	131,500	227,500	299,880
Exercised (in shares)			(4,692)
Forfeited (in shares)			(70,331)
Outstanding at the end of the reporting period (in shares)	1,234,967		1,234,967
Number of Options Exercisable
Exercisable at the beginning of the year (in shares)			704,303
Vested (in shares)			(114,591)	(125,880)
Forfeited (in shares)			(17,057)
Exercisable at the end of the reporting period (in shares)	797,145		797,145
Weighted Average Exercise Price Outstanding
Outstanding at the beginning of period (in dollars per share)			$ 4.87
Granted (in dollars per share)			4.77
Exercised (in dollars per share)			2.91
Forfeited (in dollars per share)			4.73
Outstanding at the end of the reporting period (in dollars per share)	$ 4.86		4.86
Weighted Average Exercise Price Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)			5.08
Vested exercisable (in dollars per share)			4.76
Forfeited (in dollars per share)			4.72
Exercisable at the end of the reporting period (in dollars per share)	5.05		5.05
Weighted Average Grant Date Fair Value Outstanding
Outstanding at the beginning of the reporting period (in dollars per share)			3
Granted (in dollars per share)			3.24
Exercised (in dollars per share)			1.75
Forfeited (in dollars per share)			2.89
Outstanding at the end of the reporting period (in dollars per share)	3.06		3.06
Weighted Average Grant Date Fair Value Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)			3.17
Vested options exercisable (in dollars per share)			2.90
Exercised options exercisable (in dollars per share)			1.75
Forfeited options exercisable (in dollars per share)			2.84
Exercisable at the end of the reporting period (in dollars per share)	$ 3.15		$ 3.15
Weighted Average Remaining Life In Years Outstanding
Outstanding Weighted Average Remaining Life (in years)			7 years 11 months 12 days		8 years 4 months 17 days
Granted (in years)			9 years 3 months 22 days
Weighted Average Remaining Life Exercisable
Exercisable, Weighted Average Remaining Life			7 years 5 months 5 days		8 years 1 month 24 days
Granted (in years)			7 years 6 months 15 days

STOCK-BASED COMPENSATION (Sto_2

STOCK-BASED COMPENSATION (Stock Options Outstanding and Exercisable) (Details) - Common stock options - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2016	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	1,234,967		1,082,490
Exercisable, Weighted Average Remaining Life	7 years 5 months 5 days	8 years 1 month 24 days
Exercisable Number of Options	797,145		704,303
$1.93 – $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	146,183
Exercisable, Weighted Average Remaining Life	7 years 4 months 2 days
Exercisable Number of Options	90,323
$1.93 – $2.00 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 1.93
$1.93 – $2.00 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 2
$3.83 – $4.92
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	646,984
Exercisable, Weighted Average Remaining Life	8 years 7 months 17 days
Exercisable Number of Options	370,907
$3.83 – $4.92 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 3.83
$3.83 – $4.92 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 4.92
$5.01 – $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	281,500
Exercisable, Weighted Average Remaining Life	6 years 15 days
Exercisable Number of Options	207,455
$5.01 – $6.00 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 5.01
$5.01 – $6.00 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 6
$6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	70,000
Exercisable, Weighted Average Remaining Life	6 years 1 month 24 days
Exercisable Number of Options	53,753
$6.18 – $7.20 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 6.18
$6.18 – $7.20 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 7.20
$7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	67,800
Exercisable, Weighted Average Remaining Life	6 years 3 months 26 days
Exercisable Number of Options	54,540
$7.54 – $7.80 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 7.54
$7.54 – $7.80 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 7.80
$8.06 – $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	22,500
Exercisable, Weighted Average Remaining Life	6 years 3 months 18 days
Exercisable Number of Options	20,167
$8.06 – $12.98 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 8.06
$8.06 – $12.98 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range (in dollars per share)	$ 12.98

STOCK-BASED COMPENSATION (Restr

STOCK-BASED COMPENSATION (Restricted Stock Activity) (Details) - Restricted stock units	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Restricted Share Units
Outstanding at beginning of year (in shares) | shares	1,476,858
Granted (in shares) | shares	1,379,905
Vested (in shares) | shares	(621,263)
Canceled (in shares) | shares	(164,201)
Outstanding at end of year (in shares) | shares	2,071,299
Weighted- Average Grant-Date Fair Value Per Share
Outstanding at beginning of year (in dollars per share) | $ / shares	$ 4.96
Granted (in dollars per share) | $ / shares	4.81
Vested (in dollars per share) | $ / shares	4.93
Canceled (in dollars per share) | $ / shares	5.16
Outstanding at end of year (in dollars per share) | $ / shares	$ 4.85

STOCK-BASED COMPENSATION (Equit

STOCK-BASED COMPENSATION (Equity Based Compensation Schedule) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Allocation of stock-based compensation expense
Stock compensation expense	$ 1,368	$ 666	$ 3,958	$ 2,024
Research and development expenses
Allocation of stock-based compensation expense
Stock compensation expense	686	324	2,033	900
Research and development expenses | Employees
Allocation of stock-based compensation expense
Stock compensation expense	672	304	1,975	839
Research and development expenses | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	14	20	58	61
General and administrative expenses
Allocation of stock-based compensation expense
Stock compensation expense	682	342	1,925	1,124
General and administrative expenses | Employees and directors
Allocation of stock-based compensation expense
Stock compensation expense	337	314	1,471	998
General and administrative expenses | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	$ 345	$ 28	$ 454	$ 126

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ 11	$ 16	$ 19	$ 40

RELATED PARTY TRANSACTION (Deta

RELATED PARTY TRANSACTION (Details) - Director - Engineering Design and Fabrication Advisory Services - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Aug. 31, 2016
Related Party Transaction [Line Items]
Related party advisory services agreement				$ 120,000
Expenses from transactions with related party	$ 0	$ 0	$ 26,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 16, 2016USD ($)ft²	May 31, 2018USD ($)ft²lease_options	May 30, 2015USD ($)	Nov. 30, 2013USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Jan. 01, 2019ft²	Dec. 31, 2017USD ($)
Operating Leases
Restricted cash, pledged mutual fund					$ 211,000		$ 211,000			$ 0
Loss contingency accrual					0	$ 0	0	$ 0
Loss in period					0	0	0	0
Corporate Headquarters
Operating Leases
Square feet of initial rental space | ft²		16,682
Term of contract		72 years
Number of operating lease renewal options | lease_options		1
Renewal term		5 years
Base rent from November 1, 2018 to July 31, 2019		$ 19,500
Base rent as of August 1, 2019		$ 25,774
Increase in rental payments (as a percent)		3.00%
Base rent on expansion premises from January 1, 209 to June 30, 2019		$ 7,767
Base rent on expansion premises for the month of July 2019		15,533
Base rent on expansion premises effective August 01, 2019		15,998
Monthly operating cost		11,177
Security deposit, cash		$ 50,000
Restricted cash, pledged mutual fund					211,000		211,000
Satellite development office
Operating Leases
Square feet of initial rental space | ft²	5,248
Term of contract	5 years		1 year	2 years
Monthly operating cost	$ 17,000
Rent expense			$ 5,000	$ 4,000
Facilities and equipment
Operating Leases
Rent expense					200,000	$ 127,000	484,000	$ 339,000
Forecast | Corporate Headquarters
Operating Leases
Additional square feet of rental space | ft²									10,355
Letter of Credit | Corporate Headquarters
Operating Leases
Line of Credit Facility, Maximum Borrowing Capacity					200,000		200,000
Line of Credit Facility, Annual Step Down of No Defaults					$ 50,000		$ 50,000